• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

An in vitro micromethod for drug sensitivity testing of Leishmania.

作者信息

Jackson J E, Tally J D, Tang D B

机构信息

Department of Parasitology, Walter Reed Army Institute of Research, Washington, DC.

出版信息

Am J Trop Med Hyg. 1989 Sep;41(3):318-30.

PMID:2552851
Abstract

We describe an in vitro microtest which is quantitative, rapid, and readily applicable to parasites isolated from all major forms of human leishmaniasis. It is based on drug-mediated inhibition of promastigote catabolism of a battery of simple 14C-substrates to 14CO2. Each test requires less than 1 microCi. The test is conducted in a serum-free, chemically defined medium containing 120 micrograms protein/ml, minimizing the possible interference of drug: serum protein interaction. Prior adaptation is not necessary to cultivate "difficult-to-grow" species. Leishmania sensitivity to pentavalent antimonials is detectable at micrograms levels below concentrations achievable in patients' sera.

摘要

相似文献

1
An in vitro micromethod for drug sensitivity testing of Leishmania.
Am J Trop Med Hyg. 1989 Sep;41(3):318-30.
2
Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.治疗前从患者分离出的维氏利什曼原虫对葡糖胺锑钠的敏感性。
J Parasitol. 1999 Apr;85(2):360-6.
3
Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions.婴儿利什曼原虫:五价锑的阶段特异性活性与检测条件相关。
Exp Parasitol. 2000 Jul;95(3):209-14. doi: 10.1006/expr.2000.4537.
4
Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.人类利什曼原虫(维扬尼利什曼原虫)感染中的锑耐药性与治疗失败
J Infect Dis. 2006 May 15;193(10):1375-83. doi: 10.1086/503371. Epub 2006 Apr 7.
5
In vivo antileishmanial properties of pentavalent antimonial compounds.
Trans R Soc Trop Med Hyg. 1982;76(2):284. doi: 10.1016/0035-9203(82)90305-4.
6
Antileishmaniasis activity of flavonoids from Consolida oliveriana.来自奥利弗飞燕草的黄酮类化合物的抗利什曼病活性。
J Nat Prod. 2009 Jun;72(6):1069-74. doi: 10.1021/np8008122.
7
The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis.吡唑并嘧啶与五价锑对杜氏利什曼原虫和巴西利什曼原虫的协同作用。
Am J Trop Med Hyg. 1988 Sep;39(3):250-5. doi: 10.4269/ajtmh.1988.39.250.
8
Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.五价锑对杜氏利什曼原虫体外无鞭毛体的阶段特异性活性。
Antimicrob Agents Chemother. 1999 Feb;43(2):278-82. doi: 10.1128/AAC.43.2.278.
9
Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.利什曼病中的耐药性:其在皮肤和黏膜皮肤疾病全身化疗中的意义。
Am J Trop Med Hyg. 1992 Jul;47(1):117-26. doi: 10.4269/ajtmh.1992.47.117.
10
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.对五价锑治疗无反应患者的利什曼原虫属进行体外药物效力和药敏性定量评估。
Am J Trop Med Hyg. 1990 Nov;43(5):464-80. doi: 10.4269/ajtmh.1990.43.464.

引用本文的文献

1
Visceral leishmaniasis: experimental models for drug discovery.内脏利什曼病:药物发现的实验模型。
Indian J Med Res. 2011 Jan;133(1):27-39.
2
Canine visceral leishmaniasis, United States and Canada, 2000-2003.2000 - 2003年美国和加拿大的犬内脏利什曼病
Emerg Infect Dis. 2006 Mar;12(3):440-6. doi: 10.3201/eid1203.050811.
3
In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced.喷他脒耐药无鞭毛体的体外生命周期:化学抗性表型的稳定性取决于诱导的抗性水平。
Antimicrob Agents Chemother. 1997 Sep;41(9):1898-903. doi: 10.1128/AAC.41.9.1898.
4
Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.口服双(苄基)多胺类似物对杜氏利什曼原虫的抑制作用
Antimicrob Agents Chemother. 1991 Jul;35(7):1403-7. doi: 10.1128/AAC.35.7.1403.